蕁麻疹治療薬の世界市場2018-2022...市場調査レポートについてご紹介

【英文タイトル】Global Urticaria Drugs Market 2018-2022

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
• Urticaria pipeline analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: BY TYPE OF DRUG
• Segmentation by type of drug
• Antihistamines
• Anti-inflammatory agents
• Sulfones
• Biologics
PART 09: MARKET SEGMENTATION BY APPLICATION
• Segmentation by application
• Comparison by application
• Acute urticaria – Market size and forecast 2017-2022
• Chronic urticaria – Market size and forecast 2017-2022
• Market opportunity by application
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• EMEA – Market size and forecast 2017-2022
• Americas – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
• Introduction of biologics for the treatment of urticaria
• International guidelines for diagnosis and management of urticaria
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• F. Hoffmann-La Roche (Genentech)
• JDP Therapeutics
• Meiji Holdings
• Novartis
• Taiho Pharmaceutical
PART 17: APPENDIX
• List of abbreviations
PART 18: EXPLORE TECHNAVIO



Exhibit 01: Parent market
Exhibit 02: Global dermatological drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs for urticaria
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global – Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global – Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2017
Exhibit 19: Application – Market share 2017-2022 (%)
Exhibit 20: Comparison by application
Exhibit 21: Acute urticaria – Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Acute urticaria – Year-over-year growth 2018-2022 (%)
Exhibit 23: Chronic urticaria – Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Chronic urticaria – Year-over-year growth 2018-2022 (%)
Exhibit 25: Market opportunity by application
Exhibit 26: Customer landscape
Exhibit 27: Global – Market share by geography 2017-2022 (%) 57
Exhibit 28: Regional comparison 58
Exhibit 29: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 30: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 31: Top 3 countries in EMEA
Exhibit 32: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 33: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in Americas
Exhibit 35: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 36: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Market opportunity
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: F. Hoffmann-La Roche (Genentech) – Overview
Exhibit 45: F. Hoffmann-La Roche (Genentech) – Business segments
Exhibit 46: F. Hoffmann-La Roche (Genentech) – Organizational developments
Exhibit 47: F. Hoffmann-La Roche (Genentech) – Geographic focus
Exhibit 48: F. Hoffmann-La Roche (Genentech) – Segment focus
Exhibit 49: F. Hoffmann-La Roche (Genentech) – Key offerings
Exhibit 50: JDP Therapeutics – Overview
Exhibit 51: JDP Therapeutics – Business segments
Exhibit 52: JDP Therapeutics – Organizational developments
Exhibit 53: JDP Therapeutics – Key offerings
Exhibit 54: Meiji Holdings – Overview
Exhibit 55: Meiji Holdings – Organizational developments
Exhibit 56: Meiji Holdings – Key offerings
Exhibit 57: Novartis – Overview
Exhibit 58: Novartis – Business segments
Exhibit 59: Novartis – Organizational development
Exhibit 60: Novartis – Geographic focus
Exhibit 61: Novartis – Segment focus
Exhibit 62: Novartis – Key offerings
Exhibit 63: Taiho Pharmaceutical – Overview
Exhibit 64: Novartis – Organizational developments
Exhibit 65: Taiho pharmaceutical – Key offerings



【レポート販売概要】

■ タイトル:蕁麻疹治療薬の世界市場2018-2022
■ 英文:Global Urticaria Drugs Market 2018-2022
■ 発行日:2018年12月20日
■ 調査会社:Technavio
■ 商品コード:IRTNTR23857
■ 調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。